P53 mutation and LOH at chromosome 9 in urothelial carcinoma

Anticancer Research

Volumn 32, Issue 2, 2012, Pages 523-527

  Beothe, Tamas ^a,b   Nagy, Anetta ^a   Farkas, Laszlo ^b   Kovacs, Gyula ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF PÉCS   (Hungary)

Author keywords

Chromosome 17p LOH; Chromosome 9 LOH; Developmental pathway; p53 mutation; Urothelial carcinoma

Indexed keywords

MICROSATELLITE DNA; PROTEIN P53;

ALLELE; ARTICLE; CANCER GENETICS; CANCER STAGING; CARCINOMA IN SITU; CELL PROLIFERATION; CHROMOSOME 9; DISEASE ASSOCIATION; GENE LOCUS; GENE MUTATION; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; PAPILLARY CARCINOMA; PRIORITY JOURNAL; TRANSITIONAL CELL CARCINOMA; TUMOR SUPPRESSOR GENE;

ALLELES; CASE-CONTROL STUDIES; CHROMOSOMES, HUMAN, PAIR 17; CHROMOSOMES, HUMAN, PAIR 9; EXONS; GENES, P53; HUMANS; LOSS OF HETEROZYGOSITY; MICROSATELLITE REPEATS; MUTATION; NEOPLASM GRADING; NEOPLASM STAGING; UROLOGIC NEOPLASMS;

EID: 84856846649     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Goebell PJ and Knowles MA: Bladder cancer or bladder cancers? Genetically distinct malignant conditions of the urothelium. Urol Oncol 28: 409-428, 2010.
2. Spruck CH IIIrd, Ohneseit PF, Gonzalez-Zulueta M, Esrig D, Miyao N, Thai YC, Lerner SP, Schmütte C, Yang AS, Cote R, Dubeau L, Nichols PW, Hermann GG, Steven K, Horn T, Skinner DG and Jones PA: Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 54: 784-788, 1994.
3. Reznikoff CA, Belair CD, Yeager TR, Savelieva E, Bleiloch RH, Puthenveettil JA and Cuthill S: A molecular genetic model of human bladder cancer pathogenesis. Semin Oncol 23: 571-584, 1996. (Pubitemid 26362217)
4. Schäffer AA, Simon R, Desper R, Richter J and Sauter G: Tree models for dependent copy number changes in bladder cancer. Int J Oncol 18: 349-354, 2001.
5. Bulashevska S, Szakacs O, Brors B, Eils R and Kovacs G: Pathways of urothelial cancer progression suggested by Bayesian network analysis of allelotyping data. Int J Cancer 110: 850-856, 2004. (Pubitemid 38758511)
6. Langbein S, Szakacs O, Wilhelm M, Sukosd F, Weber S, Jauch A, Lopez Beltran A, Alken P, Kälble T and Kovacs G: Alteration of the LRPlB gene region is associated with high grade of urothelial cancer. Lab Invest 82: 639-643, 2002. (Pubitemid 34522376)
7. Hernandez S, Lopez-Knowles E, Lloreta J, Kogevinas M, Jaramillo R, Amorós A, Tardón A, Garcia-Closas R, Serra C, Carrato A, Malats N and Real FX: FGFR3 and Tp53 mutations in T1G3 transitional bladder carcinomas: independent distribution and lack of association with prognosis. Clin Cancer Res 11: 5444-5450, 2005. (Pubitemid 41060820)
8. Veeriah S, Brennan C, Meng S, Singh B, Fagin JA, Solit DB, Paty PB, Rohle D, Vivanco I, Chmielecki J, Pao W, Ladanyi M, Gerald WL, Liau L, Cloughesy TC, Mischel PS, Sander C, Taylor B, Schultz N, Major J, Heguy A, Fang F, Mellinghoff IK and Chan TA: The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers. Proc Natl Acad Sci USA 106: 9435-9440, 2009.
9. Stallings RL, Nair P, Maris JM, Catchpoole D, McDermott M, O'Meara A and Breatnach F: High-resolution analysis of chromosomal breakpoints and genomic instability identifies PTPRD as a candidate tumor suppressor gene in neuroblastoma. Cancer Res 66: 3673-3680, 2006.
10. Solomon DA, Kim JS, Cronin JC, Sibenaller Z, Ryken T, Rosenberg SA, Ressom H, Jean W, Bigner D, Yan H, Samuels Y and Waldman T: Mutational inactivation of PTPRD in glioblastoma multiforme and malignant melanoma. Cancer Res 68: 10300-10306, 2008.
11. Kohno T, Otsuka A, Girard L, Sato M, Iwakawa R, Ogiwara H, Sanchez-Cespedes M, Minna JD and Yokota J: A catalog of genes homozygously deleted in human lung cancer and the candidacy of PTPRD as a tumor suppressor gene. Genes Chromosomes Cancer 49: 342-352, 2010.
12. Giefing M, Zemke N, Brauze D, Kostrzewska-Poczekaj M, Luczak M, Szaumkessel M, Pelinska K, Kiwerska K, Tönnies H, Grenman R, Figlerowicz M, Siebert R, Szyfter K and Jarmuz M: High resolution arrayCGH and expression profiling identifies PTPRD and PCDH17/PCH68 as tumor suppressor gene candidates in laryngeal squamous cell carcinoma. Genes Chromosomes Cancer 50: 154-166, 2011.
13. Akagi T, Ito T, Kato M, Jin Z, Cheng Y, Kan T, Yamamoto G, Olaru A, Kawamata N, Boult J, Soukiasian HJ, Miller CW, Ogawa S, Meltzer SJ and Koeffler HP: Chromosomal abnormalities and novel disease-related regions in progression from Barrett's esophagus to esophageal adenocarcinoma. Int J Cancer 125: 2349-2359, 2009.
14. Serrano M, Hannon GJ and Beach D: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366: 704-747, 1993.
15. Tada Y, Wada M, Taguchi K, Mochida Y, Kinugawa N, Tsuneyoshi M, Naito S and Kuwano M: The association of death-associated protein kinase hypermethylation with early recurrence in superficial bladder cancer. Cancer Res 62: 4048-4053, 2002. (Pubitemid 34791073)
16. Catto JW, Azzouzi AR, Rehman I, Feeley KM, Cross SS, Amira N, Fromont G, Sibony M, Cussenot O, Meuth M and Hamdy FC: Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma. J Clin Oncol 23: 2903-2910, 2005. (Pubitemid 46224108)
17. Neuhausen A, Florl AR, Grimm MO and Schulz WA: DNA methylation alterations in urothelial carcinoma. Cancer Biol Ther 5: 993-1001, 2006.
18. Chan MW, Chan LW, Tang NL, Tong JH, Lo KW, Lee TL, Cheung HY, Wong WS, Chan PS, Lai FM and To KF: Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients. Clin Cancer Res 8: 464-470, 2002. (Pubitemid 34193966)
19. Deiss LP, Feinstein E, Berissi H, Cohen O and Kimchi A: Identification of a novel serine/threonine kinase and a novel 15-kD protein as potential mediators of the interferon-induced cell death. Genes Dev 9: 15-30, 1995.
20. Raveh T, Droguett G, Horwitz MS, DePinho RA and Kimchi A: DAP kinase activates a p19ARF/p53-mediated apoptotic checkpoint to suppress oncogenic transformation. Nat Cell Biol 3: 1-7, 2001. (Pubitemid 32114825)
21. McGarvey TW, Maruta Y, Tomaszewski JE, Linnenbach AJ and Malkowicz SB: PTCH gene mutations in invasive transitional cell carcinoma of the bladder. Oncogene 17: 1167-1172, 1998. (Pubitemid 28444601)
22. Habuchi T, Yoshida O and Knowles MA: A novel candidate tumor suppressor locus at 9q32.33 in bladder cancer: localisation of the candidate region within a single 840 kb YAC. Hum Mol Genet 6: 913-919, 1997. (Pubitemid 27239077)
23. Hornigold N, Devlin J, Davies AM, Avayard JS, Habuchi T and Knowles MA: Mutation of the 9q34 gene TSC1 in sporadic bladder cancer. Oncogene 18: 2657-2661, 1999. (Pubitemid 29216689)
24. Pymar LS, Platt FM, Askham JM, Morrison EE and Knowles MA: Bladder tumor derived somatic TSC1 missense mutation cause loss of function via distinct mechanisms. Hum Mol Genet 17: 2006-2017, 2008. (Pubitemid 351865849)
25. Hartmann A, Moser K, Kriegmair M, Hostetter A, Hofstaedter F and Knuechel R: Frequent genetic alterations in simple urothelial hyperplasias of the bladder in patients with papillary urothelial carcinoma. Am J Pathol 154: 721-727, 1999. (Pubitemid 29122590)
26. Chow NH, Cairns P, Eisenberger CF, Schoenberg MP, Taylor DC, Epstein JI and Sidransky D: Papillary urothelial hyperplasia is a clonal precursor to papillary transitional cell bladder cancer. Int J Cancer 89: 514-518, 2000.
27. Hartmann A, Schlake G, Zaak D, Hungerhuber E, Hofstetter A, Hofstaedter F and Knuechel R: Occurrence of chromosome 9 and p53 alterations in multifocal dysplasia and carcinoma in situ of human urinary bladder. Cancer Res 62: 809-818, 2002. (Pubitemid 34126958)
28. Cho Y, Gorina S, Jeffrey PD and Pavletich NP: Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 265: 346-355, 1994. (Pubitemid 24259959)